PCVX · Vaxcyte Inc. Common Stock
View on chartInsiders & Stakes
| Grant Pickering Chief Executive Officer | ▼ Sell | Tax Withholding | 429,902 Shares held | 9/8/2026 | View profile |
| Fairman Jeff VP, Research | ▼ Sell | Open Market | 286,227 Shares held | 10/26/2022 | View profile |
| Jim Wassil EVP, Chief Scientific Ofc, COO | ▼ Sell | Open Market | 145,435 Shares held | 10/5/2026 | View profile |
| Andrew Guggenhime President and CFO | ▼ Sell | Tax Withholding | 95,316 Shares held | 9/8/2026 | View profile |
| Harpreet S. Dhaliwal SVP Cml Mfg & Supply Chain | ▼ Sell | Tax Withholding | 68,085 Shares held | 9/8/2026 | View profile |
| Jodar Luis Chief Medical Officer | ▲ Buy | Grant | 52,632 Shares held | 9/4/2026 | View profile |
| Eydelman Mikhail SVP, Gen Counsel & Corp Sec | ▼ Sell | Open Market | 41,620 Shares held | 3/5/2025 | View profile |
| Elvia Cowan SVP, Finance & CAO | ▼ Sell | Open Market | 27,860 Shares held | 10/5/2026 | View profile |
| Heath Lukatch Director | ▲ Buy | Grant | 19,481 Shares held | 6/15/2026 | View profile |
| Sauer Paul SVP Process Dev, Manufacturing | ▼ Sell | Tax Withholding | 13,822 Shares held | 9/2/2022 | View profile |
| Halley E. Gilbert Director | ▲ Buy | Grant | 12,481 Shares held | 6/15/2026 | View profile |
| Teri Loxam Director | ▲ Buy | Grant | 12,481 Shares held | 6/15/2026 | View profile |
| Anne S. Drapeau Director | ▲ Buy | Grant | 12,481 Shares held | 6/15/2026 | View profile |
| Hirth Peter Director | ▲ Buy | Grant | 7,175 Shares held | 6/6/2024 | View profile |
| Carlos Paya V Director | ▲ Buy | Grant | 6,856 Shares held | 6/15/2026 | View profile |
| Jacks Lee Director | ▲ Buy | Grant | 6,856 Shares held | 6/15/2026 | View profile |
| Kamarck Michael E. Director | ▲ Buy | Grant | 5,625 Shares held | 6/13/2023 | View profile |
| John Furey Director | ▲ Buy | Grant | 5,306 Shares held | 6/15/2026 | View profile |
| Olivier Brandicourt Director | ▲ Buy | Grant | 4,699 Shares held | 6/15/2026 | View profile |
| Wright-Mitchell Jane Chief Legal Officer | ▼ Sell | Open Market | 3,125 Shares held | 8/16/2021 | View profile |
Transaction History
| Jim Wassil | ▲ Buy | Option Exercise | 18,000 | $96K | 10/5/2026 |
| Jim Wassil | ▼ Sell | Open Market | 18,000 | $1.6M | 10/5/2026 |
| Elvia Cowan | ▲ Buy | Option Exercise | 19,000 | $492K | 10/5/2026 |
| Elvia Cowan | ▼ Sell | Open Market | 19,000 | $1.6M | 10/5/2026 |
| Jim Wassil | ▲ Buy | Option Exercise | 2,250 | $12K | 10/1/2026 |
| Jim Wassil | ▼ Sell | Open Market | 2,155 | $122K | 10/1/2026 |
| Jim Wassil | ▼ Sell | Open Market | 95 | $5K | 10/1/2026 |
| Jim Wassil | ▼ Sell | Open Market | 1,334 | $79K | 9/9/2026 |
| Grant Pickering | ▼ Sell | Tax Withholding | 17,056 | $1.0M | 9/8/2026 |
| Andrew Guggenhime | ▼ Sell | Tax Withholding | 7,155 | $432K | 9/8/2026 |
| Harpreet S. Dhaliwal | ▼ Sell | Tax Withholding | 7,651 | $462K | 9/8/2026 |
| Elvia Cowan | ▼ Sell | Tax Withholding | 1,327 | $80K | 9/8/2026 |
| Jim Wassil | ▼ Sell | Tax Withholding | 5,459 | $330K | 9/8/2026 |
| Jim Wassil | ▼ Sell | Open Market | 1,381 | $84K | 9/4/2026 |
| Jodar Luis | ▲ Buy | Grant | 52,632 | $0 | 9/4/2026 |
| Grant Pickering | ▼ Sell | Tax Withholding | 3,427 | $211K | 9/2/2026 |
| Andrew Guggenhime | ▼ Sell | Tax Withholding | 1,432 | $88K | 9/2/2026 |
| Harpreet S. Dhaliwal | ▼ Sell | Tax Withholding | 659 | $41K | 9/2/2026 |
| Elvia Cowan | ▼ Sell | Tax Withholding | 326 | $20K | 9/2/2026 |
| Jim Wassil | ▼ Sell | Tax Withholding | 1,432 | $88K | 9/2/2026 |
| Jim Wassil | ▼ Sell | Open Market | 303 | $19K | 9/1/2026 |
| Jim Wassil | ▲ Buy | Option Exercise | 2,250 | $12K | 9/1/2026 |
| Jim Wassil | ▼ Sell | Open Market | 1,537 | $94K | 9/1/2026 |
| Jim Wassil | ▼ Sell | Open Market | 713 | $44K | 9/1/2026 |
| Jim Wassil | ▼ Sell | Open Market | 924 | $56K | 9/1/2026 |
| Jim Wassil | ▼ Sell | Tax Withholding | 1,273 | $77K | 8/31/2026 |
| Grant Pickering | ▼ Sell | Tax Withholding | 2,862 | $174K | 8/31/2026 |
| Andrew Guggenhime | ▼ Sell | Tax Withholding | 1,273 | $77K | 8/31/2026 |
| Harpreet S. Dhaliwal | ▼ Sell | Tax Withholding | 361 | $22K | 8/31/2026 |
| Elvia Cowan | ▼ Sell | Tax Withholding | 243 | $15K | 8/31/2026 |
| Harpreet S. Dhaliwal | ▲ Buy | Option Exercise | 17,000 | $421K | 8/5/2026 |
| Harpreet S. Dhaliwal | ▼ Sell | Open Market | 17,000 | $935K | 8/5/2026 |
| Jim Wassil | ▲ Buy | Option Exercise | 2,250 | $12K | 8/3/2026 |
| Jim Wassil | ▼ Sell | Open Market | 861 | $46K | 8/3/2026 |
| Jim Wassil | ▼ Sell | Open Market | 1,389 | $75K | 8/3/2026 |
| Andrew Guggenhime | ▲ Buy | Option Exercise | 10,000 | $54K | 8/3/2026 |
| Andrew Guggenhime | ▼ Sell | Open Market | 6,956 | $374K | 8/3/2026 |
| Andrew Guggenhime | ▼ Sell | Open Market | 3,044 | $165K | 8/3/2026 |
| Grant Pickering | ▼ Sell | Open Market | 622 | $35K | 7/27/2026 |
| Grant Pickering | ▲ Buy | Option Exercise | 16,198 | $33K | 7/27/2026 |
| Grant Pickering | ▼ Sell | Open Market | 11,783 | $654K | 7/27/2026 |
| Grant Pickering | ▼ Sell | Open Market | 4,415 | $247K | 7/27/2026 |
| Grant Pickering | ▼ Sell | Open Market | 756 | $42K | 7/27/2026 |
| Grant Pickering | ▼ Sell | Open Market | 244 | $14K | 7/27/2026 |
| Grant Pickering | ▼ Sell | Open Market | 378 | $21K | 7/27/2026 |
| Andrew Guggenhime | ▲ Buy | Option Exercise | 10,000 | $54K | 7/6/2026 |
| Andrew Guggenhime | ▼ Sell | Open Market | 7,913 | $452K | 7/6/2026 |
| Andrew Guggenhime | ▼ Sell | Open Market | 2,087 | $121K | 7/6/2026 |
| Jim Wassil | ▲ Buy | Option Exercise | 516 | $3K | 7/1/2026 |
| Jim Wassil | ▼ Sell | Open Market | 1,788 | $100K | 7/1/2026 |
| Jim Wassil | ▼ Sell | Open Market | 456 | $26K | 7/1/2026 |
| Jim Wassil | ▼ Sell | Open Market | 6 | $347 | 7/1/2026 |
| Grant Pickering | ▼ Sell | Open Market | 6,417 | $360K | 6/26/2026 |
| Grant Pickering | ▼ Sell | Open Market | 312 | $17K | 6/26/2026 |
| Grant Pickering | ▼ Sell | Open Market | 9,137 | $505K | 6/26/2026 |
| Grant Pickering | ▼ Sell | Open Market | 6,683 | $363K | 6/26/2026 |
| Grant Pickering | ▼ Sell | Open Market | 356 | $20K | 6/26/2026 |
| Grant Pickering | ▼ Sell | Open Market | 332 | $19K | 6/26/2026 |
| Grant Pickering | ▼ Sell | Open Market | 207 | $11K | 6/26/2026 |
| Grant Pickering | ▼ Sell | Open Market | 602 | $33K | 6/26/2026 |
| Grant Pickering | ▼ Sell | Open Market | 191 | $11K | 6/26/2026 |
| Grant Pickering | ▲ Buy | Option Exercise | 225 | $403 | 6/18/2026 |
| Grant Pickering | ▼ Sell | Open Market | 22,236 | $1.2M | 6/18/2026 |
| Grant Pickering | ▼ Sell | Open Market | 1,000 | $53K | 6/18/2026 |
| Grant Pickering | ▼ Sell | Open Market | 1,000 | $53K | 6/18/2026 |
| Andrew Guggenhime | ▲ Buy | Option Exercise | 10,000 | $54K | 6/18/2026 |
| Andrew Guggenhime | ▼ Sell | Open Market | 10,000 | $530K | 6/18/2026 |
| Grant Pickering | ▼ Sell | Open Market | 225 | $12K | 6/18/2026 |
| Anne S. Drapeau | ▲ Buy | Grant | 2,265 | $0 | 6/15/2026 |
| Heath Lukatch | ▲ Buy | Grant | 2,265 | $0 | 6/15/2026 |
| Carlos Paya V | ▲ Buy | Grant | 2,265 | $0 | 6/15/2026 |
| Teri Loxam | ▲ Buy | Grant | 2,265 | $0 | 6/15/2026 |
| Olivier Brandicourt | ▲ Buy | Grant | 2,194 | $0 | 6/15/2026 |
| Halley E. Gilbert | ▲ Buy | Grant | 2,265 | $0 | 6/15/2026 |
| John Furey | ▲ Buy | Grant | 2,265 | $0 | 6/15/2026 |
| Jacks Lee | ▲ Buy | Grant | 2,265 | $0 | 6/15/2026 |
| Jim Wassil | ▼ Sell | Open Market | 301 | $15K | 6/1/2026 |
| Jim Wassil | ▼ Sell | Open Market | 1,949 | $96K | 6/1/2026 |
| Jim Wassil | ▼ Sell | Open Market | 2,250 | $128K | 5/1/2026 |
| Elvia Cowan | ▲ Buy | Option Exercise | 3,000 | $78K | 4/7/2026 |
| Elvia Cowan | ▼ Sell | Open Market | 3,000 | $180K | 4/7/2026 |
| Jim Wassil | ▼ Sell | Open Market | 1,412 | $82K | 4/1/2026 |
| Jim Wassil | ▼ Sell | Open Market | 838 | $49K | 4/1/2026 |
| Elvia Cowan | ▼ Sell | Open Market | 1,487 | $82K | 3/17/2026 |
| Elvia Cowan | ▼ Sell | Open Market | 405 | $23K | 3/17/2026 |
| Elvia Cowan | ▲ Buy | Option Exercise | 2,500 | $65K | 3/11/2026 |
| Elvia Cowan | ▼ Sell | Open Market | 2,500 | $146K | 3/11/2026 |
| Jim Wassil | ▼ Sell | Open Market | 2,427 | $142K | 3/10/2026 |
| Jim Wassil | ▼ Sell | Open Market | 4,968 | $294K | 3/10/2026 |
| Harpreet S. Dhaliwal | ▼ Sell | Tax Withholding | 604 | $36K | 3/9/2026 |
| Elvia Cowan | ▼ Sell | Tax Withholding | 495 | $29K | 3/9/2026 |
| Jim Wassil | ▼ Sell | Tax Withholding | 975 | $58K | 3/9/2026 |
| Grant Pickering | ▼ Sell | Tax Withholding | 3,685 | $219K | 3/9/2026 |
| Andrew Guggenhime | ▼ Sell | Tax Withholding | 1,021 | $61K | 3/9/2026 |
| Elvia Cowan | ▼ Sell | Tax Withholding | 326 | $20K | 3/2/2026 |
| Grant Pickering | ▼ Sell | Tax Withholding | 2,531 | $157K | 3/2/2026 |
| Harpreet S. Dhaliwal | ▼ Sell | Tax Withholding | 465 | $29K | 3/2/2026 |
| Jim Wassil | ▼ Sell | Tax Withholding | 1,009 | $63K | 3/2/2026 |
| Andrew Guggenhime | ▼ Sell | Tax Withholding | 1,009 | $63K | 3/2/2026 |
| Elvia Cowan | ▼ Sell | Tax Withholding | 243 | $15K | 2/28/2026 |
| Andrew Guggenhime | ▼ Sell | Tax Withholding | 898 | $56K | 2/28/2026 |
| Jim Wassil | ▼ Sell | Tax Withholding | 898 | $56K | 2/28/2026 |
| Grant Pickering | ▼ Sell | Tax Withholding | 2,863 | $177K | 2/28/2026 |
| Harpreet S. Dhaliwal | ▼ Sell | Tax Withholding | 292 | $18K | 2/28/2026 |
| Jim Wassil | ▲ Buy | Grant | 5,102 | $315K | 2/27/2026 |
| Jim Wassil | ▼ Sell | Tax Withholding | 1,900 | $117K | 2/27/2026 |
| Grant Pickering | ▲ Buy | Grant | 105,110 | $0 | 2/26/2026 |
| Elvia Cowan | ▲ Buy | Grant | 10,681 | $0 | 2/26/2026 |
| Elvia Cowan | ▲ Buy | Option Exercise | 7,716 | $200K | 2/26/2026 |
| Jim Wassil | ▲ Buy | Grant | 32,045 | $0 | 2/26/2026 |
| Harpreet S. Dhaliwal | ▲ Buy | Grant | 53,409 | $0 | 2/26/2026 |
| Andrew Guggenhime | ▲ Buy | Grant | 44,864 | $0 | 2/26/2026 |
| Olivier Brandicourt | ▲ Buy | Grant | 1,357 | $0 | 1/15/2026 |
| Andrew Guggenhime | ▼ Sell | Gift | 61,850 | $0 | 1/14/2026 |
| Andrew Guggenhime | ▼ Sell | Gift | 61,850 | $0 | 1/14/2026 |
| Grant Pickering | ▼ Sell | Gift | 100,000 | $0 | 1/14/2026 |
| Harpreet S. Dhaliwal | ▼ Sell | Open Market | 9,743 | $455K | 12/31/2025 |
| Elvia Cowan | ▼ Sell | Open Market | 4,907 | $235K | 12/23/2025 |
| Elvia Cowan | ▼ Sell | Open Market | 6,716 | $322K | 12/23/2025 |
| Elvia Cowan | ▼ Sell | Gift | 1,000 | $0 | 12/23/2025 |
| Elvia Cowan | ▼ Sell | Tax Withholding | 482 | $16K | 9/8/2025 |
| Harpreet S. Dhaliwal | ▼ Sell | Tax Withholding | 1,204 | $39K | 9/8/2025 |
| Jim Wassil | ▼ Sell | Tax Withholding | 2,759 | $89K | 9/8/2025 |
| Andrew Guggenhime | ▼ Sell | Tax Withholding | 2,890 | $94K | 9/8/2025 |
| Grant Pickering | ▼ Sell | Tax Withholding | 7,356 | $238K | 9/8/2025 |
| Elvia Cowan | ▲ Buy | Grant | 2,810 | $0 | 9/7/2025 |
| Elvia Cowan | ▼ Sell | Tax Withholding | 242 | $8K | 9/2/2025 |
| Elvia Cowan | ▼ Sell | Tax Withholding | 325 | $10K | 9/2/2025 |
| Harpreet S. Dhaliwal | ▼ Sell | Tax Withholding | 291 | $9K | 9/2/2025 |
| Harpreet S. Dhaliwal | ▼ Sell | Tax Withholding | 783 | $25K | 9/2/2025 |
| Harpreet S. Dhaliwal | ▼ Sell | Tax Withholding | 464 | $15K | 9/2/2025 |
| Jim Wassil | ▼ Sell | Tax Withholding | 1,270 | $40K | 9/2/2025 |
| Jim Wassil | ▼ Sell | Tax Withholding | 1,587 | $50K | 9/2/2025 |
| Jim Wassil | ▼ Sell | Tax Withholding | 1,429 | $45K | 9/2/2025 |
| Andrew Guggenhime | ▼ Sell | Tax Withholding | 1,270 | $40K | 9/2/2025 |
| Andrew Guggenhime | ▼ Sell | Tax Withholding | 2,381 | $75K | 9/2/2025 |
| Andrew Guggenhime | ▼ Sell | Tax Withholding | 1,429 | $45K | 9/2/2025 |
| Grant Pickering | ▼ Sell | Tax Withholding | 2,857 | $90K | 9/2/2025 |
| Grant Pickering | ▼ Sell | Tax Withholding | 4,563 | $144K | 9/2/2025 |
| Grant Pickering | ▼ Sell | Tax Withholding | 3,420 | $108K | 9/2/2025 |
| Olivier Brandicourt | ▲ Buy | Grant | 1,148 | $0 | 6/12/2025 |
| Halley E. Gilbert | ▲ Buy | Grant | 3,041 | $0 | 6/12/2025 |
| Teri Loxam | ▲ Buy | Grant | 3,041 | $0 | 6/12/2025 |
| Heath Lukatch | ▲ Buy | Grant | 3,041 | $0 | 6/12/2025 |
| John Furey | ▲ Buy | Grant | 3,041 | $0 | 6/12/2025 |
| Jacks Lee | ▲ Buy | Grant | 3,041 | $0 | 6/12/2025 |
| Anne S. Drapeau | ▲ Buy | Grant | 3,041 | $0 | 6/12/2025 |
| Carlos Paya V | ▲ Buy | Grant | 3,041 | $0 | 6/12/2025 |
| Heath Lukatch | ▲ Buy | Option Exercise | 6,000 | $96K | 4/8/2025 |
| Heath Lukatch | ▲ Buy | Option Exercise | 1,000 | $21K | 4/8/2025 |
| Andrew Guggenhime | ▲ Buy | Option Exercise | 4,777 | $100K | 4/7/2025 |
| Grant Pickering | ▲ Buy | Option Exercise | 15,781 | $84K | 4/4/2025 |
| Grant Pickering | ▲ Buy | Option Exercise | 4,752 | $99K | 4/4/2025 |
| Grant Pickering | ▲ Buy | Grant | 57,938 | $0 | 3/27/2025 |
| Eydelman Mikhail | ▼ Sell | Open Market | 112 | $8K | 3/5/2025 |
| Eydelman Mikhail | ▲ Buy | Option Exercise | 5,000 | $107K | 3/5/2025 |
| Eydelman Mikhail | ▼ Sell | Open Market | 2,621 | $184K | 3/5/2025 |
| Eydelman Mikhail | ▼ Sell | Open Market | 2,267 | $161K | 3/5/2025 |
| Andrew Guggenhime | ▼ Sell | Tax Withholding | 3,809 | $275K | 3/3/2025 |
| Elvia Cowan | ▼ Sell | Tax Withholding | 325 | $23K | 3/3/2025 |
| Eydelman Mikhail | ▼ Sell | Tax Withholding | 616 | $44K | 3/3/2025 |
| Jim Wassil | ▲ Buy | Option Exercise | 2,638 | $6K | 3/3/2025 |
| Jim Wassil | ▲ Buy | Option Exercise | 5,362 | $29K | 3/3/2025 |
| Jim Wassil | ▼ Sell | Open Market | 5,915 | $432K | 3/3/2025 |
| Jim Wassil | ▼ Sell | Open Market | 2,085 | $154K | 3/3/2025 |
| Jim Wassil | ▼ Sell | Tax Withholding | 3,015 | $217K | 3/3/2025 |
| Grant Pickering | ▼ Sell | Tax Withholding | 7,984 | $576K | 3/3/2025 |
| Andrew Guggenhime | ▼ Sell | Tax Withholding | 1,270 | $93K | 2/28/2025 |
| Elvia Cowan | ▼ Sell | Tax Withholding | 242 | $18K | 2/28/2025 |
| Eydelman Mikhail | ▼ Sell | Tax Withholding | 470 | $34K | 2/28/2025 |
| Jim Wassil | ▲ Buy | Grant | 5,649 | $412K | 2/28/2025 |
| Jim Wassil | ▼ Sell | Tax Withholding | 2,869 | $209K | 2/28/2025 |
| Jim Wassil | ▼ Sell | Tax Withholding | 1,270 | $93K | 2/28/2025 |
| Grant Pickering | ▼ Sell | Tax Withholding | 2,013 | $147K | 2/28/2025 |
| Andrew Guggenhime | ▲ Buy | Grant | 22,761 | $0 | 2/27/2025 |
| Elvia Cowan | ▲ Buy | Grant | 5,379 | $0 | 2/27/2025 |
| Eydelman Mikhail | ▲ Buy | Grant | 14,484 | $0 | 2/27/2025 |
| Jim Wassil | ▲ Buy | Grant | 21,726 | $0 | 2/27/2025 |
| Andrew Guggenhime | ▲ Buy | Option Exercise | 8,000 | $43K | 2/18/2025 |
| Andrew Guggenhime | ▼ Sell | Open Market | 6,182 | $517K | 2/18/2025 |
| Andrew Guggenhime | ▼ Sell | Open Market | 1,818 | $154K | 2/18/2025 |
| Eydelman Mikhail | ▲ Buy | Option Exercise | 5,000 | $107K | 2/5/2025 |
| Eydelman Mikhail | ▼ Sell | Open Market | 571 | $50K | 2/5/2025 |
| Eydelman Mikhail | ▼ Sell | Open Market | 635 | $57K | 2/5/2025 |
| Eydelman Mikhail | ▼ Sell | Open Market | 1,755 | $158K | 2/5/2025 |
| Eydelman Mikhail | ▼ Sell | Open Market | 1,784 | $162K | 2/5/2025 |
| Eydelman Mikhail | ▼ Sell | Open Market | 255 | $23K | 2/5/2025 |
| Jim Wassil | ▲ Buy | Option Exercise | 8,000 | $19K | 2/3/2025 |
| Jim Wassil | ▼ Sell | Open Market | 5,314 | $457K | 2/3/2025 |
| Jim Wassil | ▼ Sell | Open Market | 2,666 | $231K | 2/3/2025 |
| Jim Wassil | ▼ Sell | Open Market | 20 | $2K | 2/3/2025 |
| Andrew Guggenhime | ▲ Buy | Option Exercise | 8,000 | $43K | 1/21/2025 |
| Andrew Guggenhime | ▼ Sell | Open Market | 5,318 | $458K | 1/21/2025 |
| Andrew Guggenhime | ▼ Sell | Open Market | 1,999 | $174K | 1/21/2025 |
| Andrew Guggenhime | ▼ Sell | Open Market | 683 | $60K | 1/21/2025 |
| Teri Loxam | ▲ Buy | Option Exercise | 6,250 | $142K | 1/15/2025 |
| Teri Loxam | ▼ Sell | Open Market | 146 | $12K | 1/15/2025 |
| Teri Loxam | ▼ Sell | Open Market | 215 | $18K | 1/15/2025 |
| Teri Loxam | ▼ Sell | Open Market | 1,136 | $94K | 1/15/2025 |
| Teri Loxam | ▼ Sell | Open Market | 1,202 | $101K | 1/15/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints
Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints. Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.